http://orcid.org/0000-0002-0672-9041
We thank Dr. Kapoor and colleagues from the MD Anderson Cancer Centre for their comments and for sharing their insights on HIPEC associated complications. We agree that in addition to the type, dose and duration of exposure to the chemotherapeutic agent, the use of multiple agents in HIPEC will likely have a significant impact on complications. The systemic and intraperitoneal administration of cisplatin has been associated with hypocalcaemia owing to its nephrotoxic effects [Citation1,Citation2], but we could only find one case report linking it with hypophosphatemia [Citation3].
As oncologists, we believe that we must strike a balance between the efficacy of our treatments (HIPEC) and its potential complications, in order to deliver the best care to our patients. We too, encourage further evaluation in this area, and believe that this knowledge will certainly translate to better patient care.
Disclosure statement
No potential conflict of interest was reported by the authors.
References
- Somashekhar SP, Prasanna G, Jaka R, et al. Hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: a single institution Indian experience. Natl Med J India. 2016;29:262–266.
- Baradaran A, Tavafi M, Ardalan MR, Rafieian-Kopaei M. Cisplatin; nephrotoxicity and beyond. Ann Res Antioxid. 2016;1:e014.
- Elazzazy S, El-Geed HA, Yafei SA. Severe hypophosphatemia induced after first cycle of the ESHAP protocol for Hodgkin’s lymphoma: a case report. Int Med Case Rep J. 2013;6:1–5.